Comparison of lupus nephritis induction treatments in a hispanic population: A single-center cohort analysis

Journal of Rheumatology

Volumn 42, Issue 11, 2015, Pages 2082-2091

  Mejía Vilet, Juan Manuel ^a   Arreola Guerra, José Manuel ^a   Córdova Sánchez, Bertha M ^a   Morales Buenrostro, Luis Eduardo ^a   Uribe Uribe, Norma O ^a   Correa Rotter, Ricardo ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Cyclophosphamide; Hispanic; Lupus nephritis; Mexican mestizo; Mycophenolate mofetil azathioprine

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MESTIZO; MEXICAN; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RENAL FLARE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL; VASCULAR LESION; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EVALUATION STUDY; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KIDNEY FUNCTION TEST; LUPUS NEPHRITIS; MEXICO; MORTALITY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TEACHING HOSPITAL; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; ANALYSIS OF VARIANCE; AZATHIOPRINE; BIOPSY, NEEDLE; COHORT STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, TEACHING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; MALE; MEXICO; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946605404     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150395     Document Type: Article

References (25)

1. Dooley MA. Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2007:1112-30.
2. Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology 2009;48:542-5.
3. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40.
4. Ponticelli C, Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 1998;7:635-8.
5. Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 2011;70:393-4.
6. Korbet SM, Schwartz MM, Evans J, Lewis EJ; Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244-54.
7. Durán S, Apte M, Alarcón GS; LUMINA Study Group. Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. J Natl Med Assoc 2007; 99:1196-8.
8. Radhakrishnan J. Lupus nephritis: keeping the wolf at bay. Clin J Am Soc Nephrol 2013;8:136-7.
9. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 2010; 49:128-40.
10. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983;75:382-91.
11. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sánchez-Guerrero J, et al; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-26.
12. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009;18:257-63.
13. Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol 2011;75:233-41.
14. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
15. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005;14:890-5.
16. Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol 2009; 5:212-20.
17. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
18. Mok CC, Ying KY, Lau CS, Yim CW, Ng WL, Wong WS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004;43:269-76.
19. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
20. Koo HS, Kim YC, Lee SW, Kim DK, Oh KH, Joo KW, et al. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus 2011;20:1442-9.
21. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-95.
22. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
23. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047-53.
24. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
25. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008;3:46-53.